Company news

Arbutus Biopharma Corporation news in 2020

Arbutus Biopharma Corporation's news releases, calls and decks from 2020, newest first.

View company

Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

December 9, 2020

Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects

November 15, 2020

Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting

November 14, 2020

Arbutus to Present at Jefferies Virtual London Healthcare Conference

November 9, 2020

Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update

October 28, 2020

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

October 12, 2020

Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference

September 27, 2020

Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

September 14, 2020

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference

September 8, 2020

Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

August 26, 2020

Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 6, 2020

Arbutus to Report Second Quarter 2020 Financial Results

July 28, 2020

Arbutus to Present at Jefferies Virtual Healthcare Conference

May 26, 2020

Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

May 17, 2020

Arbutus to Present at UBS Virtual Global Healthcare Conference

May 11, 2020

Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections

May 10, 2020

Arbutus to Report First Quarter 2020 Financial Results

May 3, 2020

Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B

March 25, 2020

Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update

March 4, 2020

Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results

February 26, 2020

Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

February 9, 2020

Decks in 2020